Methods of Administering Microparticles Combined With Autologous Body Components

1 - 95 . (canceled)

96 . A tissue treatment implant, comprising:

a bulking agent comprising a plurality of microparticles pre-loaded within a mixing and delivery system; and

an autologous carrier comprising bodily fluid withdrawn from a patient into said mixing and delivery system;

wherein said bulking agent and said autologous carrier are combined within the mixing and delivery system and then delivered to a treatment location within said patient.

97 . The tissue treatment implant of claim 96 , wherein the autologous carrier comprises blood, serum or plasma.

98 . The tissue treatment implant of claim 96 , wherein the autologous carrier comprises cerebral spinal fluid, lymph, synovial fluid, extracellular fluid, amniotic fluid, or milk.

99 . The tissue treatment implant of claim 96 , wherein the autologous carrier is subjected to sterile filtration before combining with the plurality of microparticles.

100 . The tissue treatment implant of claim 96 , wherein the plurality of microparticles have average diameters between about 10 microns and about 500 microns.

101 . The tissue treatment implant of claim 96 , wherein the plurality of microparticles comprise smooth surfaces free from corners, edges, peaks and projections.

102 . The tissue treatment implant of claim 96 , wherein the plurality of microparticles comprise one or more of elliptical and cylindrical forms.

103 . The tissue treatment implant of claim 96 , wherein the plurality of microparticles comprise non-smooth surfaces.

104 . The tissue treatment implant of claim 96 , wherein the plurality of microparticles comprise a porous surface, a porous body, a shell-like structure, a hollow interior, a metallic coating, a carbon coating, or a carbon nanotube coating.

105 . The tissue treatment implant of claim 96 , wherein the plurality of microparticles have a short-term effectiveness of up to about 6 months, a medium-term effectiveness of up to about 3 years, or a long-term effectiveness of more than about 3 years.

106 . The tissue treatment implant of claim 96 , wherein the plurality of microparticles comprise polylactic acid, a ceramic material, polymethacrylate, polymethylmethacrylate (PMMA), polypropylene, polytetrafluoroethylene (PTFE), or purified cytoskeleton of unicellular or multicellular algae.

107 . The tissue treatment implant of claim 96 , wherein the plurality of microparticles are sterile.

108 . The tissue treatment implant of claim 96 , further comprising sterile water, an aqueous isotonic solution of saline, an aqueous isotonic solution of phosphate salts, a hypertonic aqueous solution, or a hypotonic solution.

109 . The tissue treatment implant of claim 96 , further comprising a sterile aqueous thickening agent.

110 . The tissue treatment implant of claim 109 , wherein the sterile aqueous thickening agent comprises collagen, gelatin, hyaluronic acid, methyl-cellulose, or polylactic acid.

111 . The tissue treatment implant of claim 96 , wherein the mixing and delivery system further comprises a metered aspiration syringe.

112 . The tissue treatment implant of claim 111 , wherein the metered aspiration syringe further comprises a rotatable metering sleeve.

113 . The tissue treatment implant of claim 111 , wherein the metered aspiration syringe further comprises a micronizing device.

114 . The tissue treatment implant of claim 113 , wherein the micronizing device comprises a structure configured to perform physical micronization, a structure configured to perform ultrasonic micronization, or combinations thereof.

115 . The tissue treatment implant of claim 96 , further comprising an agent to assist in homogeneity, a coagulant agent, an agent to facilitate bonding, or an adhesion prevention agent.

116 . The tissue treatment implant of claim 96 , further comprising an antibiotic, an anesthetic, or an anti-inflammatory agent.